高危乳腺癌从辅助化疗到新辅助化疗：米兰癌症研究所的经验。1992年施泰纳奖讲座 - Suppr

Suppr

超能文献

From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992.

作者信息

Bonadonna G

机构信息

Department of Medicine, Istituto Nazionale Tumori, Milan, Italy.

出版信息

Int J Cancer. 1993 Aug 19;55(1):1-4. doi: 10.1002/ijc.2910550102.

DOI:10.1002/ijc.2910550102

PMID:8344741

Abstract

摘要

相似文献

From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992.高危乳腺癌从辅助化疗到新辅助化疗：米兰癌症研究所的经验。1992年施泰纳奖讲座

Int J Cancer. 1993 Aug 19;55(1):1-4. doi: 10.1002/ijc.2910550102.

Contributions to the understanding and management of breast cancer. Steiner Award Lecture 1992.对乳腺癌理解与管理的贡献。1992年施泰纳奖讲座

Int J Cancer. 1993 Sep 9;55(2):179-80. doi: 10.1002/ijc.2910550202.

Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute.高危乳腺癌多学科治疗的当前及未来趋势。米兰癌症研究所的经验。

Eur J Cancer. 1996 Feb;32A(2):209-14. doi: 10.1016/0959-8049(95)00612-5.

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.（新）辅助化疗对BRCA1和BRCA2相关乳腺癌的毒性作用

Breast Cancer Res Treat. 2016 Apr;156(3):557-566. doi: 10.1007/s10549-016-3777-0. Epub 2016 Apr 9.

Exploring Decision-Making about Neo-adjuvant Chemotherapy for Breast Cancer.探索乳腺癌新辅助化疗的决策制定

Breast J. 2016 Jan-Feb;22(1):133-4. doi: 10.1111/tbj.12537. Epub 2015 Nov 4.

Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.个体化辅助治疗：历史的教训：2013 年圣加仑奖得主的开幕词。

Breast. 2013 Aug;22 Suppl 2:S3-7. doi: 10.1016/j.breast.2013.07.001.

Aromatase inhibitors as adjuvant therapy for breast cancer.芳香化酶抑制剂作为乳腺癌的辅助治疗

J Clin Oncol. 2009 May 20;27(15):2566-7. doi: 10.1200/JCO.2009.22.2695. Epub 2009 Mar 30.

The Feasibility and Tolerability of Newer Chemotherapy Regimens in the Adjuvant Setting in Older Patients with Breast Cancer.新型化疗方案用于老年乳腺癌患者辅助治疗的可行性和耐受性

Breast J. 2016 Mar-Apr;22(2):244-6. doi: 10.1111/tbj.12559. Epub 2015 Dec 20.

Adjuvant therapy for breast cancer.乳腺癌辅助治疗

NIH Consens Statement. 2000;17(4):1-35.

Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy.接受辅助化疗和新辅助化疗的早期乳腺癌患者的急诊科就诊情况。

Intern Med J. 2018 May;48(5):583-587. doi: 10.1111/imj.13785.

引用本文的文献

Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.白细胞介素6（IL-6）的表达与人类乳腺癌中的雌激素受体相关。

Br J Cancer. 1999 May;80(3-4):579-84. doi: 10.1038/sj.bjc.6690394.

The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury.使用精氨酸-甘氨酸-天冬氨酸（RGD）的合成类似物和肿瘤坏死因子可溶性受体预防急性和慢性实验性肝损伤。

Yale J Biol Med. 1997 Jul-Aug;70(4):391-402.

Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice.精氨酸-甘氨酸-天冬氨酸模拟物及肿瘤坏死因子可溶性受体作为小鼠伴刀豆球蛋白A诱导性肝炎治疗方式的分析

Gut. 1997 Jan;40(1):133-8. doi: 10.1136/gut.40.1.133.

Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group.米托蒽醌/长春瑞滨方案的诱导化疗能否使可手术的局部区域性乳腺癌患者接受保乳治疗？法国北部肿瘤学组对105例患者的试验。法国北部肿瘤学组

Breast Cancer Res Treat. 1996;40(2):161-9. doi: 10.1007/BF01806211.

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.促黄体生成素释放激素（LH-RH）的细胞毒性类似物（T-98）对雌激素依赖性MXT小鼠乳腺癌生长的影响：肿瘤生长特征与表皮生长因子（EGF）受体含量之间的相关性

Breast Cancer Res Treat. 1996;40(2):129-39. doi: 10.1007/BF01806208.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验